India to hit Roche, BMS with compulsory licenses on 3 cancer drugs FiercePharma The Indian patent office revoked IP protection on Pfizer's ($PFE) kidney and liver cancer drug Sutent, and pulled the patent on Roche's hepatitis C treatment Pegasys. Meanwhile, the courts have dawdled over challenges to generic versions of still-on ... |
